Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury
Georgene W Hergenroeder, Anthony N Moore, J Philip McCoy Jr, Leigh Samsel, Norman H Ward 3rd, Guy L Clifton, Pramod K Dash, Georgene W Hergenroeder, Anthony N Moore, J Philip McCoy Jr, Leigh Samsel, Norman H Ward 3rd, Guy L Clifton, Pramod K Dash
Abstract
Background: Increased intracranial pressure (ICP) is a serious, life-threatening, secondary event following traumatic brain injury (TBI). In many cases, ICP rises in a delayed fashion, reaching a maximal level 48-96 hours after the initial insult. While pressure catheters can be implanted to monitor ICP, there is no clinically proven method for determining a patient's risk for developing this pathology.
Methods: In the present study, we employed antibody array and Luminex-based screening methods to interrogate the levels of inflammatory cytokines in the serum of healthy volunteers and in severe TBI patients (GCS<or=8) with or without incidence of elevated intracranial pressure (ICP). De-identified samples and ELISAs were used to confirm the sensitivity and specificity of IL-6 as a prognostic marker of elevated ICP in both isolated TBI patients, and polytrauma patients with TBI.
Results: Consistent with previous reports, we observed sustained increases in IL-6 levels in TBI patients irrespective of their ICP status. However, the group of patients who subsequently experienced ICP >or= 25 mm Hg had significantly higher IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained <or=20 mm Hg. When blinded samples (n = 22) were assessed, a serum IL-6 cut-off of <5 pg/ml correctly identified 100% of all the healthy volunteers, a cut-off of >128 pg/ml correctly identified 85% of isolated TBI patients who subsequently developed elevated ICP, and values between these cut-off values correctly identified 75% of all patients whose ICP remained <or=20 mm Hg throughout the study period. In contrast, the marker had no prognostic value in predicting elevated ICP in polytrauma patients with TBI. When the levels of serum IL-6 were assessed in patients with orthopedic injury (n = 7) in the absence of TBI, a significant increase was found in these patients compared to healthy volunteers, albeit lower than that observed in TBI patients.
Conclusions: Our results suggest that serum IL-6 can be used for the differential diagnosis of elevated ICP in isolated TBI.
Figures
References
- Stocchetti N, Colombo A, Ortolano F, Videtta W, Marchesi R, Longhi L. Time course of intracranial hypertension after traumatic brain injury. J Neurotrauma. 2007;24:1339–1346. doi: 10.1089/neu.2007.0300.
- Dearden NM. Mechanisms and prevention of secondary brain damage during intensive care. Clin Neuropathol. 1998;17:221–228.
- Jantzen JP. Prevention and treatment of intracranial hypertension. Best Pract Res Clin Anaesthesiol. 2007;21:517–538. doi: 10.1016/j.bpa.2007.09.001.
- Kadhim HJ, Duchateau J, Sebire G. Cytokines and brain injury: invited review. J Intensive Care Med. 2008;23:236–249. doi: 10.1177/0885066608318458.
- Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874. doi: 10.1038/nature01323.
- Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, Kuwabara K. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke. 2004;35:677–681. doi: 10.1161/01.STR.0000116876.96334.82.
- Patel RT, Deen KI, Youngs D, Warwick J, Keighley MR. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg. 1994;81:1306–1308. doi: 10.1002/bjs.1800810914.
- Minambres E, Cemborain A, Sanchez-Velasco P, Gandarillas M, az-Reganon G, Sanchez-Gonzalez U. Correlation between transcranial interleukin-6 gradient and outcome in patients with acute brain injury. Crit Care Med. 2003;31:933–938. doi: 10.1097/01.CCM.0000055370.66389.59.
- Berger RP, Ta'asan S, Rand A, Lokshin A, Kochanek P. Multiplex assessment of serum biomarker concentrations in well-appearing children with inflicted traumatic brain injury. Pediatr Res. 2008;65:97–102. doi: 10.1203/PDR.0b013e31818c7e27.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829. doi: 10.1097/00003246-198510000-00009.
- Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2:81–84. doi: 10.1016/S0140-6736(74)91639-0.
- Association for the Advancement of Automotive Medicine. Abbreviated Injury Scale (AIS) 2005 - Update 2008. Barrington, IL: AAAM Publications; 2008.
- Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS. Comparison of the interleukin-6 and interleukin-10 response in children after severe traumatic brain injury or septic shock. Acta Neurochir Suppl (Wien) 1997;70:96–97.
- Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock. 1995;4:311–317. doi: 10.1097/00024382-199511000-00001.
- Cui X, Kalsotra A, Robida AM, Matzilevich D, Moore AN, Boehme CL. Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation. Biochim Biophys Acta. 2003;1619:325–331.
- Basu A, Krady JK, O'Malley M, Styren SD, DeKosky ST, Levison SW. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci. 2002;22:6071–6082.
- John GR, Lee SC, Song X, Rivieccio M, Brosnan CF. IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia. 2005;49:161–176. doi: 10.1002/glia.20109.
- Murphy PG, Grondin J, Altares M, Richardson PM. Induction of interleukin-6 in axotomized sensory neurons. J Neurosci. 1995;15:5130–5138.
- Ringheim GE, Burgher KL, Heroux JA. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain. J Neuroimmunol. 1995;63:113–123. doi: 10.1016/0165-5728(95)00134-4.
- Goodman JC, Van M, Gopinath SP, Robertson CS. Pro-inflammatory and pro-apoptotic elements of the neuroinflammatory response are activated in traumatic brain injury. Acta Neurochir Suppl. 2008;102:437–439. full_text.
- Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol. 1999;101:211–221. doi: 10.1016/S0165-5728(99)00148-4.
- Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock. 1995;4:311–317. doi: 10.1097/00024382-199511000-00001.
- Hans VH, Kossmann T, Joller H, Otto V, Morganti-Kossmann MC. Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma. Neuroreport. 1999;10:409–412.
- Singhal A, Baker AJ, Hare GM, Reinders FX, Schlichter LC, Moulton RJ. Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury. J Neurotrauma. 2002;19:929–937. doi: 10.1089/089771502320317087.
- Chiaretti A, Genovese O, Aloe L, Antonelli A, Piastra M, Polidori G. Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst. 2005;21:185–193. doi: 10.1007/s00381-004-1032-1.
- Winter CD, Pringle AK, Clough GF, Church MK. Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain. 2004;127:315–320. doi: 10.1093/brain/awh039.
- Chiaretti A, Antonelli A, Mastrangelo A, Pezzotti P, Tortorolo L, Tosi F. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma. 2008;25:225–234. doi: 10.1089/neu.2007.0405.
- Arand M, Melzner H, Kinzl L, Bruckner UB, Gebhard F. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Arch Surg. 2001;386:241–248. doi: 10.1007/s004230100204.
- Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–512. doi: 10.1016/S0002-9343(99)00066-2.
- Oto J, Suzue A, Inui D, Fukuta Y, Hosotsubo K, Torii M. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth. 2008;22:207–212. doi: 10.1007/s00540-008-0639-x.
- Stangl M, Zerkaulen T, Theodorakis J, Illner W, Schneeberger H, Land W. Influence of brain death on cytokine release in organ donors and renal transplants. Transplant Proc. 2001;33:1284–1285. doi: 10.1016/S0041-1345(00)02479-9.
- Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28:2940–2947. doi: 10.1038/onc.2009.180.
- Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86:1154–1159. doi: 10.1210/jc.86.3.1154.
- Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S. Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) 2008;13:593–600. doi: 10.1111/j.1440-1797.2008.01021.x.
- Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab. 2000;20:956–966. doi: 10.1097/00004647-200006000-00008.
- Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol. 1999;163:3963–3968.
- Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J. Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia. 2000;32:271–285. doi: 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>;2-5.
- Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–577.
- Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother. 1994;48:445–453. doi: 10.1016/0753-3322(94)90005-1.
- Beagley KW, Elson CO. Cells and cytokines in mucosal immunity and inflammation. Gastroenterol Clin North Am. 1992;21:347–366.
- Zhang Y, Lin JX, Vilcek J. Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem. 1988;263:6177–6182.
- Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y. Interleukin 6 and expression of its receptor on epidermal keratinocytes. Cytokine. 1990;2:381–387. doi: 10.1016/1043-4666(90)90069-6.
- Loppnow H, Libby P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res. 1989;8:293–299.
- Hensler T, Sauerland S, Bouillon B, Raum M, Rixen D, Helling HJ. Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase. J Trauma. 2002;52:962–970. doi: 10.1097/00005373-200205000-00023.
- Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res. 2002;947:131–139. doi: 10.1016/S0006-8993(02)02920-7.
- Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma. 2004;21:1553–1561. doi: 10.1089/neu.2004.21.1553.
- Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma. 2000;17:113–122. doi: 10.1089/neu.2000.17.113.
- Shore PM, Thomas NJ, Clark RS, Adelson PD, Wisniewski SR, Janesko KL. Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma. 2004;21:1113–1122. doi: 10.1089/neu.2004.21.1113.
- Dash PK, Zhao J, Hergenroeder GW, Moore AN. Biomarkers fof the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics. pp. 100–114.
- Dash PK, Redell JB, Hergenroeder GW, Zhao J, Clifton GL, Moore AN. Serum ceruloplasmin and copper are early biomarkers of elevated intracranial pressure. J Neurosci Res. in press .
Source: PubMed